AOD 9604

Drug Profile

AOD 9604

Alternative Names: Advanced Obesity Drug 9604; AOD9604; Tyr-hGH171191

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Monash University
  • Developer Metabolic Pharmaceuticals
  • Class Obesity therapies; Pancreatic hormones; Peptide fragments; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Osteoporosis
  • Discontinued Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoporosis in Australia (PO)
  • 16 Sep 2008 Preclinical pharmacodynamics data presented at the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2008)
  • 21 Feb 2007 Discontinued - Phase-II for Obesity in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top